ImmunityBio shares surge 11.03% intraday on improved Q3 revenue and narrowed net loss from Anktiva demand.

ImmunityBio surged 11.03% intraday following renewed investor attention after its third-quarter results highlighted rising product revenue driven by stronger demand for Anktiva and a narrowed net loss year-over-year. The update signaled improving financial stability, with sales growth narrowing losses, which may have temporarily buoyed sentiment despite the stock’s broader 20% monthly decline and -58% one-year shareholder return. The Jefferies London Healthcare Conference presentation also contributed to ongoing investor evaluation of the company’s long-term growth potential amid volatility. A separate $16 million investment referenced in recent news could further support short-term optimism, though its impact remains speculative due to incomplete details.